ADA 2020: Medtronic Explains Strategy To Return Growth To Diabetes Business
Medtronic will launch its next-generation MiniMed 780G insulin pump while continuing to develop complementary technologies to close the competitive gap with its rivals in the diabetes market.
You may also be interested in...
Results of the ADAPT study presented at the Advanced Technologies & Treatments for Diabetes conference in Barcelona support Medtronic’s hope that the 780g insulin pump will help to turn around its diabetes business or make it an attractive acquisition for another company.
Dallara is joining Medtronic from Honeywell, where she served as CEO of the conglomerate’s Connected Enterprise. The company also promoted Mike Marinaro to the president of Medtronic’s surgical robotics unit and Kweli Thomson to lead the cardiac rhythm management unit.
During its recent quarterly earnings call, Medtronic CEO Geoff Martha reiterated that the company expects to announce changes over the next year that will help it drive growth and shareholder value. Analysts suspect Medtronic’s struggling diabetes business is probably the top candidate for a sale.